IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

Core Insights - IMUNON, Inc. is advancing its lead candidate IMNN-001, a DNA-mediated immunotherapy, in the Phase 3 OVATION 3 Study for newly diagnosed advanced ovarian cancer, aiming to be the first frontline immunotherapy for this condition [1][2][3] Recent Developments - The company hosted an R&D Day on November 10, 2025, showcasing progress in the OVATION 3 Study and presenting new data on IMNN-001's potential to transform treatment for advanced ovarian cancer [3][4] - IMUNON has reported strong Phase 2 OVATION 2 survival data and interim results from a minimal residual disease (MRD) study, which support a clear regulatory path for IMNN-001 [2][4] Financial Results - For the third quarter of 2025, IMUNON reported a net loss of $3.4 million, or $1.16 per share, a decrease from a net loss of $4.8 million, or $3.76 per share, in the same quarter of 2024 [13] - Operating expenses for the third quarter of 2025 were $3.5 million, down 30% from $5.0 million in the third quarter of 2024 [13][16] - For the nine months ended September 30, 2025, the company reported a net loss of $10.3 million, or $5.53 per share, compared to a net loss of $14.6 million, or $14.13 per share, for the same period in 2024 [19] Clinical Insights - Data from the Phase 2 OVATION 2 trial indicated a median overall survival benefit of 13 months with IMNN-001 plus standard of care chemotherapy, which is clinically meaningful compared to standard care alone [4][6] - The treatment has shown a favorable safety profile and the ability to create a "hot" tumor microenvironment by increasing anti-tumor immune responses [6][9] Strategic Initiatives - The company is focused on conserving cash and aligning critical needs with available capital while exploring financing opportunities to support the OVATION 3 trial [2][4] - IMUNON is actively seeking strategic partnerships to leverage its PlaCCine DNA technology platform for vaccine development, aiming to address unmet needs in infectious diseases and cancer [12][26]